section name header

Information

Editors

PaulaKauppi

Treatment of Acute Exacerbation of Asthma

See also picture Principles of treatment of acute exacerbation of asthma in emergency services 1.

See also Management of acute expiratory airflow obstruction and exacerbation of asthma in children Management of Acute Expiratory Airflow Obstruction and Exacerbation of Asthma in Children.

Essentials

  • The patient, family members, and the physician often underestimate the severity of an acute exacerbation of asthma.
  • The aim of the treatment is
    • to restore the condition and the pulmonary functions of the patient to the best possible level as soon as possible
    • to maintain an optimal functional status and to prevent exacerbations.

Recognition of an acute exacerbation of asthma

  • In a person with asthma, occurrence of even one of the following signs means that the attack is severe:
    • wheezing and dyspnoea have increased so that the patient cannot finish one sentence without stopping for breath, or cannot stand up from a chair
    • respiratory frequency constantly 30/min or more
    • heart rate constantly 100-120/min or more (> 30 minutes after salbutamol inhalation)
    • PEF less than 50% of the best previous value
    • oxygen saturation below 90%
    • the condition of the patient deteriorates despite treatment.

Signs indicating a life-threatening attack

  • Silent respiration sounds in auscultation
  • Cyanosis
  • Bradycardia or hypotension
  • Exhaustion, confusion or unconsciousness
  • Arterial blood pO2<8 kPa even after breathing extra oxygen, arterial pCO2>6 kPa or decreased pH

Workup

  • PEF or FEV1 in the beginning of the treatment and in the follow-up
  • Pulse oximetry (reveals hypoxia, but not hypercapnia)
  • Heart rate and blood pressure
  • Arterial blood gas analysis in severe conditions; repeated as needed
  • Plasma potassium and blood glucose
  • ECG in elderly patients
  • Chest x-ray in severe and poorly responding cases to exclude pneumothorax, pulmonary infiltrates, infections and pulmonary oedema
  • Exclusion of sinusitis Acute Maxillary Sinusitis

Immediate treatment Inhaled Magnesium Sulfate in the Treatment of Acute Asthma

  1. Put the patient in a comfortable sitting position, legs down if possible, so that he/she can bend forward if needed and have support for the hands and legs.
  2. Give oxygen (usually 35% concentration is enough; in resuscitation, maximal concentration and flow) at the rate of 4-5 l/min either through mask or nasal cannulas. If the patient also has COPD Chronic Obstructive Pulmonary Disease (COPD), a lower oxygen flow rate (1-2 l/min) is sufficient in order to avoid CO2 retention.
  3. Give salbutamol aerosol 0.1 mg/dose 4-8 puffs with a spacer Holding Chambers (Spacers) Versus Nebulisers for Beta-Agonist Treatment of Acute Asthma in Adults. Repeat if needed every 20-30 minutes 2-4 times. Alternatively, give a combination of salbutamol 2.5 mg and ipratropium bromide 0.5 mg Ipratropium as an Adjunct to Beta2 Agonists for Acute Asthma nebulized, with or without oxygen (or a combination of fenoterol 1.25 mg and ipratropium bromide 0.5 mg). Repeat after 1 hour if needed.
  4. Give glucocorticoid intravenously or orally (e.g. 40 mg methyl prednisolone or 125-250 mg hydrocortisone). Oral glucocorticoid therapy (e.g. 30-40 mg prednisolone) is started independent of the intravenous glucocorticoid as soon as the patient is able to swallow.
  5. Continue oral glucocorticoid therapy (e.g. prednisolone 30-40 mg in the morning) for several days. If the patient has continuous glucocorticoid medication at home he/she may require a higher dose.
  6. In a life-threatening and severe acute asthma attack, when the bronchodilating medication does not show sufficient effect, consider giving
  7. If the attack is prolonged, the patient may be dehydrated because dyspnoea prevents drinking. The patient may need fluids 2 000-3 000 ml in excess of normal diurnal need. Caution is needed with old patients and those with heart disease!
  8. Non-invasive ventilation (NIV) may be considered in a unit with the possibility for continous monitoring.
  9. Selection of a bronchodilating beta-2 agonist and route of administration
    • In an emergency department setting, the preferred treatment is
      • aerosol dispensers with an inhalation spacer (better pulmonary deposition than with powder) or
      • nebulizable medications for a more severe exacerbation (better pulmonary deposition than with powder, larger single dose than in aerosols, cheaper and more ecological than an aerosol).

Indications for intensive care

  • Persistent severe dyspnoea despite inhaled beta-2 agonist given with an inhalation spacer 3-4 times at 20-30-min intervals or beta-2 agonist given repeatedly with a nebulizer.
  • Arterial blood pO2 is below 8 kPa despite breathing of extra oxygen
  • Arterial blood pCO2 is over 6 kPa
  • Exhaustion
  • Confusion, drowsiness
  • Unconsciousness
  • Respiratory arrest

Further treatment

  • The patient should not be left alone until their condition has clearly improved.
  • Continue oxygen therapy as needed.
  • Continue oral glucocorticoid therapy (e.g. 30-40 mg prednisolone/day).
  • If the condition is improving, continue nebulization treatment at 4-hour intervals.
  • If the condition has not improved, repeat nebulization treatment in 20-30 minutes.
  • Sedative drugs must not be used in exacerbation of asthma, except in intensive care units.
  • Antimicrobial drugs are not indicated if there are no signs of a bacterial infection.

Hospital discharge after acute exacerbation of asthma

    References

    • [Asthma]. A Current Care Guideline. Working group appointed by The Finnish Medical Society Duodecim, Finnish Respiratory Society, Finnish Paediatric Society and Finnish Society for Clinical Physiology. Helsinki: Finnish Medical Society Duodecim, 2022 (accessed 28 May 2024). Available in Finnish at http://www.kaypahoito.fi/hoi06030.
    • Global Initiative for Asthma. Global strategy for asthma management and prevention, 2024. Updated May 2024. http://ginasthma.org/reports/
    • Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J 2019;54(3) [PubMed]